Abstract:BACKGROUND AND PURPOSE:Ginsenosides are bioactive saponins derived from Panax notoginseng roots (Sanqi) and ginseng. Here, the molecular mechanisms governing differential pharmacokinetics of 20(S)-protopanaxatriol-type ginsenoside Rg1 , ginsenoside Re and notoginsenoside R1 and 20(S)-protopanaxadiol-type ginsenosides Rb1, Rc and Rd were elucidated.EXPERIMENTAL APPROACH:Interactions of ginsenosides with human and rat hepatobiliary transporters were characterized at the cellular and vesicular levels. A rifampin-based inhibition study in rats evaluated the in vivo role of organic anion-transporting polypeptide (Oatp)1b2. Plasma protein binding was assessed by equilibrium dialysis. Drug-drug interaction indices were calculated to estimate potential for clinically relevant ginsenoside-mediated interactions due to inhibition of human OATP1Bs.KEY RESULTS:All the ginsenosides were bound to human OATP1B3 and rat Oatp1b2 but only the 20(S)-protopanaxatriol-type ginsenosides were transported. Human multidrug resistance-associated protein (MRP)2/breast cancer resistance protein (BCRP)/bile salt export pump (BSEP)/multidrug resistance protein-1 and rat Mrp2/Bcrp/Bsep also mediated the transport of the 20(S)-protopanaxatriol-type ginsenosides. Glomerular-filtration-based renal excretion of the 20(S)-protopanaxatriol-type ginsenosides was greater than that of the 20(S)-protopanaxadiol-type counterparts due to differences in plasma protein binding. Rifampin-impaired hepatobiliary excretion of the 20(S)-protopanaxatriol-type ginsenosides was effectively compensated by the renal excretion in rats. The 20(S)-protopanaxadiol-type ginsenosides were potent inhibitors of OATP1B3.CONCLUSION AND IMPLICATIONS:Differences in hepatobiliary and in renal excretory clearances caused markedly different systemic exposure and different elimination kinetics between the two types of ginsenosides. Caution should be exercised with the long-circulating 20(S)-protopanaxadiol-type ginsenosides as they could induce hepatobiliary herb-drug interactions, particularly when patients receive long-term therapies with high-dose i.v. Sanqi or ginseng extracts.

Microsomal Cytochrome P450-Mediated Metabolism of Protopanaxatriol Ginsenosides: Metabolite Profile, Reaction Phenotyping, and Structure-Metabolism Relationship.

Identification of 20(S)-Protopanaxatriol Metabolites in Rats by Ultra-Performance Liquid Chromatography Coupled with Electrospray Ionization Quadrupole Time-of-flight Tandem Mass Spectrometry and Nuclear Magnetic Resonance Spectroscopy.

Qualitatively and quantitatively investigating the metabolism of 20(S)-protopanaxadiol-type ginsenosides by gut microbiota of different species

CYP450 1A2 and multiple UGT1A isoforms are responsible for jatrorrhizine metabolism in human liver microsomes.

Metabolic Profiles of 20(S)-Protopanaxadiol in Rats after Oral Administration Using Ultra-Performance Liquid Chromatography/quadrupole Time-of-flight Tandem Mass Spectrometry.

Protopanaxadiol 6-Hydroxylase and Its Role in Regulating the Ginsenoside Heterogeneity in Panax Notoginseng Cells

Characterization of Pharmacokinetic Profiles and Metabolic Pathways of 20(S)-Ginsenoside Rh1 in Vivo and in Vitro

The inhibitory effect of intestinal bacterial metabolite of ginsenosides on CYP3A activity.

Molecular Mechanisms Governing Different Pharmacokinetics of Ginsenosides and Potential for Ginsenoside-Perpetrated Herb-Drug Interactions on Oatp1b3

Ginsenoside Metabolites, Rather Than Naturally Occurring Ginsenosides, Lead to Inhibition of Human Cytochrome P450 Enzymes

Biotransformation of Panax Ginseng Extract by Rat Intestinal Microflora: Identification and Quantification of Metabolites Using Liquid Chromatography-Tandem Mass Spectrometry

Combinatorial Metabolism Notably Affects Human Systemic Exposure to Ginsenosides from Orally Administered Extract of Panax Notoginseng Roots (Sanqi)

Identification of Human Udp-Glucuronosyltransferase 1a4 As the Major Isozyme Responsible for the Glucuronidation of 20(S)-Protopanaxadiol in Human Liver Microsomes

In Vitro/In Vivo Metabolism of Ginsenoside Rg5 in Rat Using Ultra-Performance Liquid Chromatography/Quadrupole-Time-of-Flight Mass Spectrometry

Stereoselective pharmacokinetic and metabolism studies of 20(S)- and 20(R)-ginsenoside Rg₃ epimers in rat plasma by liquid chromatography-electrospray ionization mass spectrometry.

Dose-dependent exposure profile and metabolic characterization of notoginsenoside R 1 in rat plasma by ultra-fast liquid chromatography-electrospray ionization-tandem mass spectrometry.

Metabolism of 20(S)-Ginsenoside Rg2 by Rat Liver Microsomes: Bioactivation to SIRT1-Activating Metabolites

The Inhibitory Effect of 20(S)-Protopanaxatriol (ppt) Towards Ugt1a1 and Ugt2b7

Effect of Panaxytriol on Cytochrome P450 3A4 Via the Pregnane X Receptor Regulatory Pathway.

Structure-activity Relationship and Substrate-Dependent Phenomena in Effects of Ginsenosides on Activities of Drug-Metabolizing P450 Enzymes.

Comparative Analysis on Microbial and Rat Metabolism of Ginsenoside Rb-1 by High-Performance Liquid Chromatography Coupled with Tandem Mass Spectrometry